CYP3A5 polymorphism, amlodipine and hypertension

Por: Y-P Zhang,  X-C Zuo, Z-J Huang, J-J Cai, J Wen, D D Duan y  H Yuan.   Journal of Human Hypertension (2014) 28, 145–149.

As a major cardiovascular risk factor for stroke, coronary artery disease, heart failure and end-stage renal disease, hypertension affects approximately one billion people and causes large economic burden worldwide. Cytochrome P450 3A5 (CYP3A5), belonging to the CYP3A subfamily, has been implicated in the regulation of blood pressure and may serve as a potential risk factor for the development of hypertension. Increased CYP3A5 activity could cause sodium and water retention by affecting the metabolism of cortisol in the kidneys. Furthermore, polymorphic CYP3A5 genotypes have been shown to cause differences in blood pressure response to antihypertensive drugs.

Effects of the DASH diet on blood pressure in patients with and without metabolic syndrome: results from the DASH trial

Por: Fadi Hikmat y L J Appel.   Journal of Human Hypertension (2014) 28, 170–175.

In the Dietary Approach to Stop Hypertension (DASH) trial, the DASH diet reduced blood pressure (BP) in a diverse sample of US adults. Subsequent analyses of this trial documented the efficacy of the DASH diet in several subgroups. Although subgroup analyses in individuals with metabolic syndrome (MS) have not been performed, the DASH diet has been recommended in MS patients. This paper is a subgroup analysis of the DASH trial, in which we examined the effect of study diets on BP in participants with and without MS.